System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish

PubMed: 42895282 DOI: 10.1167/tvst.15.10.27

Protection of Bevacizumab From Silicone Oil-Induced Inactivation by Liposomal Encapsulation.

Transl Vis Sci Technol 15(10):27

Authors: Sabrina Wohlfart, Niklas Junker, Hellen Gertrud Röttgen, Manuel Ben Böhmann, Victor Aristide Augustin, Gerd Uwe Auffarth, Philipp Uhl, Maximilian Hammer

Affiliations

  • David J Apple Laboratory for Vision Research, University Eye Clinic Heidelberg, Heidelberg, Germany.
  • Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Ophthalmology, University Clinic Heidelberg, Heidelberg, Germany.
  • Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany.

Abstract

PURPOSE

Silicone oil endotamponades in retinal surgery induce aggregation and thus deactivate antibody drug formulations. Liposomes represent an approach to protect and deliver these drugs when administered intravitreally; however, their interactions with silicone oil endotamponades and their influence on encapsulated antibody agents have never been investigated.

METHODS

Bevacizumab was encapsulated in liposomes using dual centrifugation. Size, polydispersity index, zeta potential, and ultrastructure were characterized using dynamic light scattering, laser Doppler electrophoresis, and electron microscopy prior to and after incubation with Siluron 1000 and Densiron Xtra for up to 4 weeks. The behavior of liposomal bevacizumab was assessed using fluorescent ATTO 488 labeling. The size and circular dichroism of bevacizumab were measured after exposure to silicone oil and lysis of the liposomes.

RESULTS

Liposomal formulations of bevacizumab were stable upon silicone oil exposure for up to 4 weeks and showed no signs of lysis or migration. Encapsulated bevacizumab remained solely intraliposomal and did not diffuse through the lipid bilayer, as tracked by fluorescence measurements. The secondary structure of the antibody was preserved throughout the study, as demonstrated by circular dichroism. In contrast to non-formulated bevacizumab, liposomal bevacizumab showed no signs of aggregation after silicone oil exposure.

CONCLUSIONS

The liposomal encapsulation of antibodies is an effective method to prevent their silicone oil-induced aggregation and inactivation. Liposomes are resistant to silicone oil exposure for a clinically relevant duration. Further in vivo studies should elucidate efficacy and release kinetics of liposomal encapsulated antibody drugs.

TRANSLATIONAL RELEVANCE

This study unravels the potential of liposomes for application in silicone oil-filled eyes.

MeSH

Endotamponade, Pharmaceutical Preparations, Silicone Oils, Liposomes, Bevacizumab, Signs And Symptoms, Silicones